Tag Archive for: Sofinnova

Weekly roundup: Awards, events, financings and 2 new episodes of Optimum TV

/in

R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease R1 Therapeutics, Inc, a clinical-stage biopharmaceutical company focused on the development of first-in-class therapies for patients with kidney disease, announced its launch with an oversubscribed $77.5 million Series A financing, along with the […]

Read more

Hot topic: Cash is starting to flow into the life science sector

/in

You have probably already seen the news: not one but two major European life science funds have closed in the last week – collectively raising a massive €1.15 billion!  Last Friday (November 14), leading European life sciences venture capital firm Medicxi announced it had closed its €500 million Medicxi V fund.  And on Monday, (November […]

Read more

Sofinnova Partners closes €650M ($750M) Capital XI, greatly exceeding initial target to back early-stage healthcare deals

/in

Total capital raised across Sofinnova’s platform reaches €1.5Bn over the past year Sofinnova Capital XI is actively investing in early-stage biotech and medtech companies across Europe and the US PARIS, France – November 17, 2025 – Sofinnova Partners (“Sofinnova”), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced the close of […]

Read more

Tulyp Medical emerges from Sofinnova’s medtech accelerator and announces FDA submission following initial first-in-human use

/in

Company unveils patented technology designed to help maintain healthy blood flow during vascular procedures Backed by Sofinnova MD Start and led by experienced medtech entrepreneurs and cardiologists PARIS, France – November 4, 2025 – Tulyp Medical, a Paris-based startup developing a medical device  for intelligent pressure-driven perfusion, emerged from stealth and announced it has submitted […]

Read more

Asceneuron Secures $100 Million Series C Financing to Advance Groundbreaking Therapeutics in Neurodegenerative Diseases

/in

Financing led by Novo Holdings, including new investment from EQT Life Sciences – LSP Dementia Fund, OrbiMed and SR One with participation from existing investors M Ventures, Sofinnova Partners, GSK Equities Investments Limited and Johnson & Johnson Innovation – JJDC, Inc. Funds will be used to progress lead asset ASN51, an oral small molecule OGA […]

Read more
© Optimum Strategic Communications.